Esketamine side effects rise sharply with higher doses, review finds
A meta-analysis of nine trials shows dose-dependent increases in nausea, dissociation, and other adverse events in treatment-resistant depression patients.
Evidence grade A · meta-analysis / systematic review. Here’s an honest read of what this study does — and doesn’t — show.
What the study found
Researchers found that esketamine was associated with significantly higher rates of nine adverse events compared with controls, including nausea, dissociation, dizziness, and elevated blood pressure. The risks were strongly dose-dependent: patients receiving higher doses (≥56 mg nasal or 0.40 mg/kg IV) experienced roughly twice the relative risk of nausea and more than triple the relative risk of dissociation compared with lower-dose groups. While esketamine was associated with improved clinical response rates, it was also linked to a 2.22-fold increase in treatment discontinuation due to adverse events.
Why it matters
The dose-response relationship for adverse events may inform discussions about individualized treatment approaches, though the study does not identify which specific patients might tolerate higher or lower doses best.
Sources
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
